- Home
- MEDP vs FITBM Comparison
MEDP vs FITBM Comparison
Compare MEDP & FITBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEDP | FITBM |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 17.2B |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | MEDP | FITBM |
|---|---|---|
| Price | $399.32 | $26.40 |
| Analyst Decision | Hold | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $490.00 | N/A |
| AVG Volume (30 Days) | ★ 351.3K | N/A |
| Earning Date | 02-09-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.98 | N/A |
| EPS | ★ 15.28 | N/A |
| Revenue | ★ $2,530,234,000.00 | N/A |
| Revenue This Year | $13.35 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | $27.74 | ★ N/A |
| Revenue Growth | ★ 19.97 | N/A |
| 52 Week Low | $250.05 | N/A |
| 52 Week High | $628.92 | N/A |
Technical Indicators
Market Signals| Indicator | MEDP | FITBM |
|---|---|---|
| Relative Strength Index (RSI) | 14.58 | N/A |
| Support Level | $538.29 | N/A |
| Resistance Level | $597.88 | N/A |
| Average True Range (ATR) | 23.88 | 0.00 |
| MACD | -20.58 | 0.00 |
| Stochastic Oscillator | 6.68 | 0.00 |
Price Performance
Historical ComparisonAbout MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.